Invesco Biotechnology & Genome ETF
PBE
74 hedge funds and large institutions have $113M invested in Invesco Biotechnology & Genome ETF in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 10 closing their positions.
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
1% more funds holding
Funds holding: 73 → 74 (+1)
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
1.52% less ownership
Funds ownership: 31.08% → 29.56% (-1.5%)
12% less capital invested
Capital invested by funds: $129M → $113M (-$16.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.87M |
| 2 |
Morgan Stanley
New York
|
+$2.26M |
| 3 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$1M |
| 4 |
HBT
Hills Bank & Trust
North Liberty,
Iowa
|
+$802K |
| 5 |
Neuberger Berman Group
New York
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$4.3M |
| 2 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$4.09M |
| 3 |
Jane Street
New York
|
-$3.96M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.17M |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$3.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
76
Niemann Capital Management
Stateline,
Nevada
| – | -$4.09M | -98,154 | Closed |
|
|
VF
77
Virtu Financial
New York
| – | -$1.89M | -45,444 | Closed |
|
|
NDSI
78
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
| – | -$1.31M | -31,525 | Closed |
|
79
Citadel Advisors
Miami,
Florida
| – | -$876K | -21,039 | Closed |
|
|
SB
80
Suntrust Banks
Atlanta,
Georgia
| – | -$397K | -9,545 | Closed |
|
81
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$280K | -6,729 | Closed |
|
|
MCM
82
Murphy Capital Management
Bedminster,
New Jersey
| – | -$217K | -5,220 | Closed |
|
83
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$42K | -1,006 | Closed |
|
|
MA
84
MUFG Americas
New York
| – | -$12K | -296 | Closed |
|
PBE Hedge Fund Activity: Q2 2014 in Review
74 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2014, worth a combined $113M — down 12% from $129M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PBE positions and 10 closed out — a net gain of 3 holders — while 19 added to existing stakes and 21 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $2.87M. The largest seller was Wells Fargo, cutting an estimated $4.3M.
- 74 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2014, up from 73 in Q1 2014.
- Funds reported $113M of Invesco Biotechnology & Genome ETF stock for Q2 2014, down 12% quarter-over-quarter.
- 13 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2014 and 10 closed out, a net change of +3 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2014 was Goldman Sachs, an estimated $2.87M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2014 was Wells Fargo, an estimated $4.3M sold.
Based on aggregated 13F filings for Q2 2014.